Cardiorenal Metabolic Disease

A post hoc analysis of the SURMOUNT-1 and SURMOUNT-2 trials found that early responders to tirzepatide, or those who lost at least 5% of body weight by 8 weeks, had greater weight loss and cardiometabolic benefits vs. non-early responders.

Presentations on the latest cardiometabolic research, panel discussions and meet-the-expert sessions are among this year’s highlights of the World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease.